Ameriprise Financial Inc. reduced its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 43.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,453,136 shares of the company’s stock after selling 1,131,229 shares during the period. Ameriprise Financial Inc. owned about 0.14% of Teva Pharmaceutical Industries worth $25,564,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Advisors Asset Management Inc. lifted its stake in Teva Pharmaceutical Industries by 16.4% in the 3rd quarter. Advisors Asset Management Inc. now owns 38,900 shares of the company’s stock worth $685,000 after acquiring an additional 5,470 shares in the last quarter. Oak Associates Ltd. OH raised its stake in shares of Teva Pharmaceutical Industries by 1.1% during the 3rd quarter. Oak Associates Ltd. OH now owns 384,224 shares of the company’s stock worth $6,762,000 after purchasing an additional 4,300 shares in the last quarter. Private Management Group Inc. raised its stake in shares of Teva Pharmaceutical Industries by 34.5% during the 3rd quarter. Private Management Group Inc. now owns 999,470 shares of the company’s stock worth $17,591,000 after purchasing an additional 256,269 shares in the last quarter. Bank Hapoalim BM raised its stake in shares of Teva Pharmaceutical Industries by 101.1% during the 3rd quarter. Bank Hapoalim BM now owns 27,953 shares of the company’s stock worth $492,000 after purchasing an additional 14,055 shares in the last quarter. Finally, GFS Advisors LLC raised its stake in shares of Teva Pharmaceutical Industries by 13.1% during the 3rd quarter. GFS Advisors LLC now owns 39,300 shares of the company’s stock worth $692,000 after purchasing an additional 4,550 shares in the last quarter. 52.05% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have recently weighed in on the company. BidaskClub downgraded Teva Pharmaceutical Industries from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 16th. Citigroup downgraded Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and cut their price target for the stock from $32.00 to $19.00 in a research note on Wednesday, August 16th. Cantor Fitzgerald set a $17.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Monday, September 11th. Royal Bank Of Canada raised their price target on Teva Pharmaceutical Industries from $8.00 to $13.00 and gave the stock an “underperform” rating in a research note on Sunday, November 5th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, September 11th. Seven analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $21.65.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded up $0.68 during midday trading on Friday, hitting $15.00. The stock had a trading volume of 15,848,000 shares, compared to its average volume of 15,675,085. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The firm has a market cap of $14,559.28, a price-to-earnings ratio of 3.31 and a beta of 0.55. Teva Pharmaceutical Industries Limited has a fifty-two week low of $10.85 and a fifty-two week high of $38.31.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 2.27%. The ex-dividend date of this dividend is Monday, November 27th. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is currently -12.10%.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/08/teva-pharmaceutical-industries-limited-teva-shares-sold-by-ameriprise-financial-inc.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.